Nyctea is on a mission to create a world with affordable medicine. This requires a new technology for purification. Nyctea is building a new purification tool that has the potential to reduce cost and increase the speed of production of biological pharmaceuticals.
Nyctea Technologies was founded in 2020 by Gustav Ferrand-Drake del Castillo and professor Andreas Dahlin at Chalmers University of Technology in Sweden.
Their research was initially focused on fundamental science, aimed to improve the understanding of polyelectrolyte brushes and their interactions with proteins. Scientific advances made during Gustav's PhD studies resulted in a method for unprecedented control of interactions between polyelectrolyte brushes and biomolecules by electrochemical signals. This resulted in a discovery of a new method for purification of biomolecules.